Pheochromocytoma Clinical Trial
Official title:
Phase 1 Study Evaluating the Safety, Distribution, Metabolism, and Radiation Dosimetry of ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma or Metastatic Carcinoid
The purpose of this study is to test the safety of a drug called Ultratrace iobenguane I 131 that has radioactivity, to measure how long it takes for the drug to be absorbed and passed out of the body, and to measure how much radioactivity is absorbed into different tissues of the body.
Status | Completed |
Enrollment | 24 |
Est. completion date | January 2007 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: Patients will enter one of two study arms depending on their type of neuroendocrine tumor. Arm P patients must: - Have a biochemical or histopathological diagnosis of either adrenal pheochromocytoma or extra-adrenal paraganglioma (biochemical diagnosis includes plasma-free metanephrines and 24-hour urine test for catecholamines/metanephrines) - Disease is metastatic or has recurred following surgery - Have a CT scan performed (for later measurement of disease volume by the core lab) within 90 days of the administration of study drug without any interventions between CT and iobenguane I 131 imaging. Arm C patients must: - Have a histopathological diagnosis of carcinoid, or by plasma chromogranin A (CgA) and 24-hour urine test for 5-hydroxyindole-acetic-acid (5HIAA) - Disease is metastatic or has recurred following surgery - Have a CT scan performed (for the later measurement of disease volume by the core lab) within 90 days of the administration of study drug without any interventions between CT and iobenguane I 131 imaging. All patients in Arm P and Arm C must also meet each of the following inclusion criteria: - Provide written informed consent and are willing to comply with protocol requirements - Are at least 18 years of age - If female, then not of childbearing potential as documented by history (e.g., tubal ligation or hysterectomy) or is post menopausal with a minimum 1 year without menses - If female of childbearing potential, has a negative serum HCG pregnancy test within 24 hours prior to receiving iobenguane I 131 - If female of childbearing potential, agrees to use an acceptable form of birth control, defined as abstinence or use of IUD, oral contraceptive, barrier and spermicide, or hormonal implant, throughout the study period Exclusion Criteria: - • Females who are nursing - Documented history of significant allergy that required medical intervention to shellfish, X-ray contrast media , iodine/iodides, or iobenguane - Administered a radioisotope within 5 effective half-lives of that radioisotope prior to study enrollment - Karnofsky performance status is < 60 - Serum creatinine > 2.0 mg/dL - Total bilirubin > 1.5 times the upper limit of normal - AST/SGOT or ALT/SGPT > 3 times the upper limit of normal - Has received an investigational compound and/or medical device within 30 days before admission into this study - Has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations - Is determined by the Investigator that the patient is clinically unsuitable for the study - Has received a medication which inhibits uptake of iobenguane I 131 within 2 weeks prior to the administration of study drug. Patients must not have taken tricyclic antidepressants or related drugs within 6 weeks prior to enrollment. |
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Molecular Insight Pharmaceuticals, Inc. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | whole body imaging immediately post-dose | |||
Primary | whole body imaging 1 hour post-dose | |||
Primary | whole body imaging 3 hours post-dose | |||
Primary | whole body imaging 6 hours post-dose | |||
Primary | whole body imaging 24 hours post-dose | |||
Primary | whole body imaging 48 hours post-dose | |||
Primary | whole body imaging 120 hours post-dose | |||
Secondary | blood and urine samples pre-dose | |||
Secondary | blood and urine samples immediately post-dose | |||
Secondary | blood and urine samples 1 hour post-dose | |||
Secondary | blood and urine samples 3 hours post-dose | |||
Secondary | blood and urine samples 6 hours post-dose | |||
Secondary | blood and urine samples 24 hours post-dose | |||
Secondary | blood and urine samples 48 hours post-dose | |||
Secondary | blood and urine samples 120 hours post-dose | |||
Secondary | continuous urine samples at intervals of 0-6 hours, 6-24 hours, 24-48 hours, 48-72 hours, 72-96 hours and 96-120 hours post-dose | |||
Secondary | monitoring for adverse events starting when the patient consents to be in the study until 2 weeks post-dose |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06050057 -
Surgical Treatment of Adrenal Diseases- Laparoscopic vs. Robotic-assisted Adrenalectomy
|
||
Recruiting |
NCT05636618 -
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03986593 -
Cryoablation of Bone Metastases From Endocrine Tumors
|
N/A | |
Terminated |
NCT05948137 -
F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma
|
||
Completed |
NCT00970970 -
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease
|
||
Active, not recruiting |
NCT00436735 -
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00669266 -
Adrenal Tumors - Pathogenesis and Therapy
|
||
Recruiting |
NCT05069220 -
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
|
Early Phase 1 | |
Recruiting |
NCT06062082 -
Intraoperative Hemodynamic Instability During Unilateral Adrenalectomy for Pheochromocytoma
|
||
Recruiting |
NCT04573816 -
Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma
|
||
Active, not recruiting |
NCT04400474 -
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
|
Phase 2 | |
Not yet recruiting |
NCT06045260 -
"Receptor Radionuclide Therapy With 177Lu-DOTATOC
|
Phase 2 | |
Completed |
NCT00001147 -
Blood Sampling for Neurochemical and Genetic Testing
|
N/A | |
Terminated |
NCT00002947 -
Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer
|
Phase 1 | |
Completed |
NCT00001229 -
Diagnosis and Treatment of Pheochromocytoma
|
N/A | |
Completed |
NCT01967576 -
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma
|
Phase 2 | |
Recruiting |
NCT03160274 -
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
|
||
Recruiting |
NCT03206060 -
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
|
Phase 2 | |
Not yet recruiting |
NCT04788927 -
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study
|
||
Enrolling by invitation |
NCT03474237 -
A Prospective Cohort Study for Patients With Adrenal Diseases
|